Nabriva Therapeutics Ag

Nabriva Therapeutics Forschungs Gmbh

Nabriva Therapeutics Gmbh

Biochemie Gesellschaft M.b.h

Werner Heilmayer

Klaus Thirring

Gerd Ascher

Rosemarie Mang

Rosemarie Riedl

Rodger Novak

Atchyuta Rama Chandra Murty Bulusu

Dirk B Strickmann

Mathias Ferencic

Lee Spence

Josef Wieser

Michael Schranz

Wolfgang Wicha

Susanne Paukner

Peter Hinsmann

Rudolf Badegruber

Dirk Strickmann

Johannes Ludescher

Johannes Hildebrandt

Hermann Kollmann

Zrinka Ivezic-Schoenfeld

Matthias Ferencic

Atchyuta Rama Bulusu

The present invention relates to an injectable pharmaceutical formulation comprising a compound of formula (I) the formulation being buffered to a pharmaceutically acceptable pH-value, especially a pH-value of from 2 to 6, in particular a pH value of from 3 to 5.5, preferred a pH-value of about 4 to 5, particularly preferred about 5.

Injectable pharmaceutical formulations of lefamulin

The present invention relates to purification methods of pleuromutilin (I) by means of crystallisation and/or recrystallisation. The process according to the present invention is carried out in the presence of i-propylacetate. 

Purification of pleuromutilin

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

12-epi pleuromutilins

Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cyclooctylsulfanyl)-acetyl]-mutilins, or 14-O-[(amino(C)alkyl-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.

Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes

Process for the preparation of a compound of formula I in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a compound of formula IIa or in a mixture of a compound of formula IIa with a compound of formula IIb and isolating a compound of formula I from the reaction mixture; compounds and salts of compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a compound of formula I.

Process for the preparation of pleuromutilins

A compound of formula (I) wherein Y is oxygen or sulfur, and X, Xand Xare independently of each other hydrogen, halogen, hydroxy or linear or branched (C)-alkoxy, or hydroxy-(C)alkyl or (C)alkoxy-(C)alkyl, mono- or dihalogenated (C)-alkyl, amino(C)-alkyl, hydroxy(C)-alkyl, with one of the two provisos that: (1) at least of X, Xand Xis other than hydrogen, and (2) Xis other than hydroxy, when Xand Xare hydrogen. 

Organic compounds

A compound of formula wherein PROT is an amine protecting group and PROT' is hydrogen; or PROT and PROT&#x2032; together with the nitrogen atom to which they are attached form a heterocyclic ring as an amine protecting group, and PROT&#x2033; is a thiol protecting group, processes for its production, intermediates in their production and production of intermediates in stereoisomerically pure form, and their use for the production of pharmaceutically active compounds.

Enantiomerically pure amines

Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation where microbes are mediating said inflammation. 

A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid. 

Pleuromutilin derivatives and their use as antimicrobials

Disclosed are pleuromutilin derivatives of formula (I) and their use in the treatment of diseases mediated by microbes.

Pleuromutilin derivatives for the treatment of diseases mediated by microbes

A pleuromutilin derivative compound of general formula (I) 

14-O&#x2014;[(((C)Alkoxy-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O&#x2014;[(((C)Mono- or dialkylamino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Guanidino-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.

The present invention relates to Compounds of general formula (I), wherein R is hydrogen and Ris hydroxy or acyloxy, or R is acyl and Ris hydroxy or acyloxy, X is sulphur, oxygen or NR, wherein Ris hydrogen or (C)alkyl; Y is sulphur or oxygen; Ris hydrogen or one or more substituents, e.g. including substituents such as conventional in organic, e.g. (pleuro)mutilin, chemistry; Ris hydrogen or (C)alkyl; Ris hydrogen or (C)alkyl; Rand R' are hydrogen, deuterium, or halogen; R, Rand Rare hydrogen, halogen or deuterium; m is a number selected from 0 to 4, n is a number selected from 0 to 10, and p is a number selected from 0 to 10; with the proviso that n plus p are at least 1. These Compounds are usef&#xfc;l as pharmaceuticals, particularly as antimicrobials. 

Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group

A compound of formula wherein the substituents have various meanings, useful as a pharmaceutical.

Growing community of inventors

Zillingtal, Austria

Werner Heilmayer